Clinical Trial Search

Primary: Percentage Change From Baseline in Seizure Frequency Per Week of Partial Onset Seizures (Type I) During the Up-titration Period — -30.88 percentage of change

Primary: Time to Beginning of Relief Based on Visual Analogue Scale (VAS) Was Defined as the Time, in Minutes, From Time of Infusion to the Beginning of Relief. — 60 minutes

Primary: Number of Participants With Treatment-related Adverse Events. — 3 Participants

Primary: Overall Response Rate (ORR) — 82 Participants

Primary: Number of Treatment Emergent Adverse Events — 103; 57; 69; 61 number of events

Primary: Percent Change in Body Weight — -3.3; 0.2 % change

Primary: Number of Participants Experiencing Dose Limiting Toxicities (DLTs) of Fresolimumab When Combined With SABR (Phase I) — 0 Participants

Primary: Percent Change in Number of Coughs Per Hour in 24 Hours Following 4 Weeks of Study Treatment — -55.16; -61.08; -65.32; -60.38 percentage change — p=0.9334

Primary: Core Phase: Percentage of Participants Who Were Alive Without Disease Progression at 6 Months — 53.8; 46.5; 53.0 Percentage of participants

Primary: Frequency of Regimen-Limiting Toxicities (RLTs) in Phase 1 Subjects — 0; 0; 0 Participants

Primary: Enrollment Rate at the End of the 6-month Recruitment Period — 111; 22; 110; 22 participants

Primary: Number of Patients Who Experienced a Dose Limiting Toxicity (DLT) — 0; 0; 0 Participants

Primary: Area Under the Curve 0-180 Minutes for Plasma Glucose >180 mg/dL — 5019.6; 4591.9; 13317.5 min*mg/dL — p=<0.0001

Primary: Overall Response Rate — 25 percentage of participants

Primary: Dose-Limiting Adverse Events — 2; 4; 6; 3 Participants